Clinical Trial Update: Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) [Phase 2]

View source ↗

Summary

Phase 2 trial DUTRENEO evaluating durvalumab and tremelimumab as neoadjuvant therapy in bladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED